guanfacine has been researched along with Feeding and Eating Disorders in 1 studies
Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.
Feeding and Eating Disorders: A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Only daytime sleepiness was more common for those receiving α2-adrenergic agonists vs stimulants (38% vs 3%); several adverse effects were reported more commonly for those receiving stimulants vs α2-adrenergic agonists, including moodiness/irritability (50% vs 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%)." | 1.62 | α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder. ( Barbaresi, W; Bax, A; Blum, NJ; Cacia, J; Deavenport-Saman, A; Friedman, S; Harstad, E; LaRosa, A; Loe, IM; Mittal, S; Shults, J; Tulio, S; Vanderbilt, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harstad, E | 1 |
| Shults, J | 1 |
| Barbaresi, W | 1 |
| Bax, A | 1 |
| Cacia, J | 1 |
| Deavenport-Saman, A | 1 |
| Friedman, S | 1 |
| LaRosa, A | 1 |
| Loe, IM | 1 |
| Mittal, S | 1 |
| Tulio, S | 1 |
| Vanderbilt, D | 1 |
| Blum, NJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for guanfacine and Feeding and Eating Disorders
| Article | Year |
|---|---|
α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2021 |